Increased HLA-G Expression in Tissue-Infiltrating Cells in Inflammatory Bowel Diseases.

Szczegóły
Abstrakt

Tytuł:: Increased HLA-G Expression in Tissue-Infiltrating Cells in Inflammatory Bowel Diseases.
Autorzy:: da Costa Ferreira S; Division of Gastroenterology, Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes 3900, Ribeirão Preto, SP, 14049-900, Brazil. .
Sadissou IA; Division of Clinical Immunology, Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Parra RS; Division of Coloproctology, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Feitosa MR; Division of Coloproctology, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Neto FSL; Molecular Biology Laboratory, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Pretti da Cunha Tirapelli D; Molecular Biology Laboratory, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Ramalho LNZ; Department of Pathology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Féres O; Division of Coloproctology, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
da Rocha JJR; Division of Coloproctology, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Donadi EA; Division of Clinical Immunology, Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
de Almeida Troncon LE; Division of Gastroenterology, Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes 3900, Ribeirão Preto, SP, 14049-900, Brazil.
Źródło:: Digestive diseases and sciences [Dig Dis Sci] 2021 Aug; Vol. 66 (8), pp. 2610-2618. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2005- : New York, NY : Springer Science + Business Media
Original Publication: New York, Plenum Pub. Corp.
MeSH Terms:: Colitis, Ulcerative/*pathology
Crohn Disease/*pathology
Gene Expression Regulation/*immunology
HLA-G Antigens/*metabolism
Adolescent ; Adult ; Female ; HLA-G Antigens/genetics ; Humans ; Inflammation ; Intestinal Mucosa/pathology ; Male ; Middle Aged ; Young Adult
References:: Baumgart D, Sandborn W. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657. (PMID: 10.1016/S0140-6736(07)60751-X)
Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–120. (PMID: 10.2147/JIR.S65979)
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A–36A. (PMID: 10.1155/2005/269076)
Van Wijk F, Cheroutre H. Mucosal T cells in gut homeostasis and inflammation. Expert Rev Clin Immunol. 2010;6:559–566. (PMID: 10.1586/eci.10.34)
Ferguson LR, Gentschew L. Inflammatory bowel disease pathogenesis. In: Advanced Nutrition and Dietetics in Gastroenterology. 2014:169–179.
Di Sabatino A, Biancheri P, Rovedatti L, MacDonald TT, Corazza GR. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:368–371. (PMID: 10.1002/ibd.21735)
Fainardi E, Castellazzi M, Stignani M, Morandi F, et al. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci. 2011;68:433–451. (PMID: 10.1007/s00018-010-0584-3)
Gonçalves MAG, Le Discorde M, Simões RT, et al. Classical and non-classical HLA molecules and p16 expression in precursors lesions and invasive cervial cancer. Eur J Obstet Gynecol Reprod Biol. 2008;141:70–74. (PMID: 10.1016/j.ejogrb.2008.06.010)
Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci. 2011;68:369–395. (PMID: 10.1007/s00018-010-0580-7)
Menier C, Rouas-Freiss N, Favier B, Lemaoult J, Moreau P, Carosella ED. Recent advaces on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens. 2010;75:201–206. (PMID: 10.1111/j.1399-0039.2009.01438.x)
Torres MI, Le Discorde M, Lorite P, et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn’s disease. Int Immunol. 2004;16:579–583. (PMID: 10.1093/intimm/dxh061)
Gomes RG, de Brito CAA, Martinelli VF, et al. HLA-G is expressed in intestinal samples of ulcerative colitis and Crohn’s disease patients and HLA-G5 expression is differentially correlated with TNF and IL-10 cytokine expression. Hum Immunol. 2018;79:477–484. (PMID: 10.1016/j.humimm.2018.03.006)
Glas J, Töök HP, Tonenchi L, et al. The 14-bp deletion polymorphism in the HLA-G gene displays significant differences between ulcerative colitis and Crohn’s disease and is associated with ileocecal resection in Crohn’s disease. Int Immunol. 2007;19:621–626. (PMID: 10.1093/intimm/dxm027)
Zidi I, Ben Yahia H, Bortolotti D, et al. Association between sHLA-G and HLA-G 14-bp deletion/insertion polymorphism in Crohn’s disease. Int Immunol. 2015;27:289–296. (PMID: 10.1093/intimm/dxv002)
Rizzo R, Bortolotti D, Baricordi OR, Fainardi E. New insights into HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11:448–463. (PMID: 10.2174/187152812803590037)
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753. (PMID: 10.1136/gut.2005.082909)
Rebmann V, LeMaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H. Quantification and identification of soluble HLA-G isoforms. Tissue Antigens. 2007;69:143–149. (PMID: 10.1111/j.1399-0039.2006.763_5.x)
Rebmann V, LeMaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H. Report of the wet workshop for quantification of soluble HLA-G in Essen, 2004. Hum Immunol. 2005;66:853–863. (PMID: 10.1016/j.humimm.2005.05.003)
Menier C, Saez B, Horejsi V, et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003;64:315–326. (PMID: 10.1016/S0198-8859(02)00821-2)
Crispim JCO, Mendes-Junior CT, Wastowski IJ, et al. Frequency of insertion/deletion polymorphism in exon 8 of HLA-G and kidney allograft outcome. Tissue Antigens. 2008;71:35–41. (PMID: 17971051)
Downs-Kelly E, Schade AE, Hansel DE. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Semin Cancer Biol. 2007;17:451–458. (PMID: 10.1016/j.semcancer.2007.07.002)
Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162–1172. (PMID: 10.1378/chest.117.4.1162)
Rizzo R, Melchiorri L, Simone L, et al. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn’s disease: a noninvasive diagnostic tool? Inflamm Bowel Dis. 2008;14:100–105. (PMID: 10.1002/ibd.20281)
Zelante A, Borgoni R, Galuppi C, et al. Therapy modifies HLA-G secretion differently in Crohn’s disease and ulcerative colitis patients. Inflamm Bowel Dis. 2011;17:E94–E95. (PMID: 10.1002/ibd.21756)
De Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27. (PMID: 10.1038/nrgastro.2015.186)
Contributed Indexing:: Keywords: Crohn’s disease; HLA-G; Inflammatory bowel disease; Inflammatory cells; Ulcerative colitis
Substance Nomenclature:: 0 (HLA-G Antigens)
Entry Date(s):: Date Created: 20200826 Date Completed: 20210922 Latest Revision: 20210922
Update Code:: 20240105
DOI:: 10.1007/s10620-020-06561-3
PMID:: 32839905
: Czasopismo naukowe

Full Text Finder

Background: Since HLA-G is an immune checkpoint molecule and since Crohn's disease (CD) and ulcerative colitis (UC) exhibit deregulated immune-mediated mechanisms, we aimed to evaluate intestinal HLA-G expression and soluble HLA-G (sHLA-G) levels in CD/UC patients stratified according to the CD phenotype/localization and UC extension.
Methods: HLA-G tissue expression was assessed by immunohistochemistry in biopsies collected from 151 patients (90 CD, 61 UC) and in surgical resection specimens (28 CD, 12 UC). Surgical material from 24 healthy controls was also assessed. Plasma sHLA-G levels (97 CD, 81 UC, and 120 controls) were evaluated using ELISA.
Results: HLA-G expression was similarly observed in the intestinal epithelial cells of control and CD/UC specimens. However, in biopsies, the plasma cells/lymphocytes infiltrating the lamina propria in CD/UC presented (1) increased HLA-G expression compared to controls (P < 0.0001), (2) greater cell staining in UC cells than in CD cells irrespective of disease extent (P = 0.0011), and (3) an increased number of infiltrating cells in the inflammatory CD phenotype compared to that in the stenosing and fistulizing phenotypes (P = 0.0407). In surgical specimens, CD/UC patients exhibited higher infiltrating cell HLA-G expression in lesion areas than in margins. sHLA-G levels were higher in UC/CD patients (P < 0.0001) than in controls, but no difference was observed between diseases.
Conclusions: Increased infiltrating cell HLA-G expression associated with increased sHLA-G levels in CD/UC patients may reflect ongoing host strategies to suppress chronic inflammation.
(© 2020. Springer Science+Business Media, LLC, part of Springer Nature.)

Informacja